Dorzolamide

• Description :

  Dorzolamide (L671152) is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity[1].

• Product Name Alternative :

  L671152; MK507

• UNSPSC :

  12352005

• Hazard Statement :

  H302

• Target :

  Carbonic Anhydrase

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Dorzolamide.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=S(C(S1)=CC2=C1S([C@@H](C)C[C@@H]2NCC)(=O)=O)(N)=O

• Molecular Formula :

  C10H16N2O4S3

• Molecular Weight :

  324.44

• Precautions :

  P264-P270-P330-P501

• References & Citations :

  [1]J Biollaz, et al. Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide. Eur J Clin Pharmacol. 1995;47 (5) :455-60.|[2]Sangly P Srinivas, et al. Inhibition of carbonic anhydrase activity in cultured bovine corneal endothelial cells by dorzolamide. Invest Ophthalmol Vis Sci. 2002 Oct;43 (10) :3273-8.|[3]Belal M Ali, et al. Dorzolamide synergizes the antitumor activity of mitomycin C against Ehrlich's carcinoma grown in mice: role of thioredoxin-interacting protein. Naunyn Schmiedebergs Arch Pharmacol. 2015 Dec;388 (12) :1271-82.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  CA II

• Citation 01 :

  Anal Chem. 2020 Dec 15;92 (24) :15745-15756.|ETH Zurich. 2020 Dec.|J Pharm Biomed Anal. 2021 Feb 20:195:113870.|ACS Environ Au. 2025 Aug 8.|Anal Chem. 2025 Jun 3;97 (21) :11099-11109.|Cell Rep. 2024 Nov 27;43 (12) :114996.|Sci Data. 2024 Sep 19;11 (1) :1024.

• CAS Number :

  [120279-96-1]